Oritavancin for CIED Infections With MDR Gram-positive Cocci

The study aimed to conduct a randomized, non-inferiority controlled trial to compare the short- and medium-term efficacy and safety of two antibiotic dosage regimens in cardiac implantable electronic devices (CIED) infections with multidrug-resistant Gram-positive cocci: 1) single-dose therapy with a long-half-life antibiotic (oritavancin) vs. standard 7-14 days of therapy with a short-half-life antibiotic (vancomycin) for CIED surgical incision site or pocket infection; and 2) fractionated therapy with a long-half-life antibiotic (oritavancin) at seven-day intervals compared to standard therapy with a short-half-life antibiotic (vancomycin) fractionated in 2-3 daily doses in cases of lead-related infectious endocarditis.

NCT Number	NCT07013552
Lead Sponsor	Medical University of Silesia Collaborators: Medical Research Agency, Poland
Conditions	Cardiac Implantable Electronic Device Infections, Infective Endocarditis, Multidrug-resistant Bacteria Screening, Gram Positive Bacterial Infection, Antibiotic Resistant Strain, Antibiotic Therapy, Healthcare Associated Infections
Enrollment	100 participants
Start Date	2025-06
Primary Completion	2026-07 (estimated)
Study Completion	2026-10 (estimated)
Updated on ClinicalTrials.gov	2025-06-10